For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
MiRNA371-Guided MAnagement in Testicular germ cell tumors- MAGMA GCT
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dr. Wassim Kassouf is a urologic oncologist working at the McGill University Health Center, the CCTG BL12 study chair and is currently a member of the clinical trials committee in genito-urinary diseases. Dr. Kassouf maintains that the BL13 trial will help evaluate whether combination therapy improves the disease control locally but also in terms of distant metastases and survival.
On Monday May 27th CCTG launched a new look for our website.
The objectives for the new look:
Strategic design principles were applied to enable our multiple target audiences to find the relevant content for them. The CCTG site has historically been a tool for the CCTG trial management audience and is now also enabled to communicate to patients and families, our partners and donors.
Website target audiences:
MAC26 (S1706) trial has been centrally activated, this is a Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG Spring meeting travel expenses are reimbursed only by submitting a properly completed travel expense claim form. This form, accompanied by original documents, should be submitted to CCTG Group Administrator’s Office no later than 30 June 2019.
Dr. Khalil Sultanem is a Radiation Oncologist working at the Jewish General Hospital at McGill University. He is involved in the Head and Neck disease site committee at CCTG and is the Co-Chair of the HN9 study. Dr. Sultanem believes the HN9 study is a unique and innovative study because it provides a possibility to replace chemotherapy, which is toxic, with immunotherapy.
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership.
A primary publication for the CCTG IND219 - A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
